Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective cohort study evaluating the extent of therapy adjustment in patients with type II diabetes mellitus (T2DM) and renal impairment (RI) treated with DPP-4 inhibitors (alogliptin, saxagliptin, and sitagliptin)

Trial Profile

A retrospective cohort study evaluating the extent of therapy adjustment in patients with type II diabetes mellitus (T2DM) and renal impairment (RI) treated with DPP-4 inhibitors (alogliptin, saxagliptin, and sitagliptin)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2018

At a glance

  • Drugs Alogliptin (Primary) ; Saxagliptin (Primary) ; Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2018 New trial record
    • 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top